Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sex hormone-binding globulin (SHBG), also known as testosterone-estradiol binding globulin, is a homodimeric glycoprotein primarily synthesized in the liver and released into the bloodstream (Hammond, 2011; Wikipedia, 2024). Its fundamental biological role is the high-affinity binding and transport of sex steroids, including testosterone, dihydrotestosterone, and estradiol, which regulates the concentration of free, biologically active hormones available to tissues (Rythm Health, 2025; Mayo Clinic, 2024). Beyond its function as a carrier protein, SHBG acts as a signaling molecule by interacting with a specific cell surface receptor (SHBG-R), where the subsequent binding of a steroid ligand triggers the activation of adenylate cyclase and increases intracellular cAMP levels (Rosner et al., 1991; PMC, 2011). Clinically, SHBG serves as a critical biomarker for metabolic and endocrine health; low serum levels are strongly associated with insulin resistance, metabolic syndrome, type 2 diabetes, and polycystic ovary syndrome (PCOS) (PMC, 2022; Superpower, 2025). Conversely, elevated SHBG levels are observed in conditions such as hyperthyroidism, liver cirrhosis, and during pregnancy or estrogen therapy (Wikipedia, 2024; Johns Hopkins, 2024). Pharmacological modulation of SHBG is a key strategy in managing hyperandrogenic states, with oral contraceptives containing ethinylestradiol being used to increase SHBG levels and thereby reduce free testosterone (Hammond, 2016; Ada Health, 2025). Understanding SHBG dynamics is essential for the accurate interpretation of hormone profiles and the optimization of therapies for reproductive and metabolic disorders (Rythm Health, 2025; Mayo Clinic, 2024).
SHBG regulates the bioavailability of sex steroids by sequestering them in the plasma, preventing their diffusion into cells (Hammond, 2011). It also functions as a ligand for the SHBG receptor (SHBG-R) on cell membranes; when a steroid binds to the SHBG-SHBG-R complex, it activates adenylate cyclase and increases intracellular cAMP levels, providing a non-genomic pathway for steroid action (Rosner et al., 1991).
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sex hormone-binding globulin (SHBG) (SHBG).